Sinju Sundaresan1, Cameron A Meininger1, Anthony J Kang1, Amanda L Photenhauer1, Michael M Hayes1, Nirakar Sahoo2, Jolanta Grembecka3, Tomasz Cierpicki3, Lin Ding1, Thomas J Giordano3, Tobias Else4, David J Madrigal5, Malcolm J Low6, Fiona Campbell7, Ann-Marie Baker8, Haoxing Xu2, Nicholas A Wright8, Juanita L Merchant9. 1. Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan. 2. Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, Michigan. 3. Department of Pathology, University of Michigan, Ann Arbor, Michigan. 4. Division of Metabolism Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan. 5. Endocrine Oncology Program, University of Michigan, Ann Arbor, Michigan. 6. Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan. 7. Department of Pathology, Royal Liverpool University Hospital, Liverpool, United Kingdom. 8. Center for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom. 9. Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan; Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan. Electronic address: merchanj@med.umich.edu.
Abstract
BACKGROUND & AIMS: The multiple endocrine neoplasia, type 1 (MEN1) locus encodes the nuclear protein and tumor suppressor menin. MEN1 mutations frequently cause neuroendocrine tumors such as gastrinomas, characterized by their predominant duodenal location and local metastasis at time of diagnosis. Diffuse gastrin cell hyperplasia precedes the appearance of MEN1 gastrinomas, which develop within submucosal Brunner's glands. We investigated how menin regulates expression of the gastrin gene and induces generation of submucosal gastrin-expressing cell hyperplasia. METHODS: Primary enteric glial cultures were generated from the VillinCre:Men1FL/FL:Sst-/- mice or C57BL/6 mice (controls), with or without inhibition of gastric acid by omeprazole. Primary enteric glial cells from C57BL/6 mice were incubated with gastrin and separated into nuclear and cytoplasmic fractions. Cells were incubated with forskolin and H89 to activate or inhibit protein kinase A (a family of enzymes whose activity depends on cellular levels of cyclic AMP). Gastrin was measured in blood, tissue, and cell cultures using an ELISA. Immunoprecipitation with menin or ubiquitin was used to demonstrate post-translational modification of menin. Primary glial cells were incubated with leptomycin b and MG132 to block nuclear export and proteasome activity, respectively. We obtained human duodenal, lymph node, and pancreatic gastrinoma samples, collected from patients who underwent surgery from 1996 through 2007 in the United States or the United Kingdom. RESULTS: Enteric glial cells that stained positive for glial fibrillary acidic protein (GFAP+) expressed gastrin de novo through a mechanism that required PKA. Gastrin-induced nuclear export of menin via cholecystokinin B receptor (CCKBR)-mediated activation of PKA. Once exported from the nucleus, menin was ubiquitinated and degraded by the proteasome. GFAP and other markers of enteric glial cells (eg, p75 and S100B), colocalized with gastrin in human duodenal gastrinomas. CONCLUSIONS: MEN1-associated gastrinomas, which develop in the submucosa, might arise from enteric glial cells through hormone-dependent PKA signaling. This pathway disrupts nuclear menin function, leading to hypergastrinemia and associated sequelae.
BACKGROUND & AIMS: The multiple endocrine neoplasia, type 1 (MEN1) locus encodes the nuclear protein and tumor suppressor menin. MEN1 mutations frequently cause neuroendocrine tumors such as gastrinomas, characterized by their predominant duodenal location and local metastasis at time of diagnosis. Diffuse gastrin cell hyperplasia precedes the appearance of MEN1 gastrinomas, which develop within submucosal Brunner's glands. We investigated how menin regulates expression of the gastrin gene and induces generation of submucosal gastrin-expressing cell hyperplasia. METHODS: Primary enteric glial cultures were generated from the VillinCre:Men1FL/FL:Sst-/- mice or C57BL/6 mice (controls), with or without inhibition of gastric acid by omeprazole. Primary enteric glial cells from C57BL/6 mice were incubated with gastrin and separated into nuclear and cytoplasmic fractions. Cells were incubated with forskolin and H89 to activate or inhibit protein kinase A (a family of enzymes whose activity depends on cellular levels of cyclic AMP). Gastrin was measured in blood, tissue, and cell cultures using an ELISA. Immunoprecipitation with menin or ubiquitin was used to demonstrate post-translational modification of menin. Primary glial cells were incubated with leptomycin b and MG132 to block nuclear export and proteasome activity, respectively. We obtained human duodenal, lymph node, and pancreatic gastrinoma samples, collected from patients who underwent surgery from 1996 through 2007 in the United States or the United Kingdom. RESULTS: Enteric glial cells that stained positive for glial fibrillary acidic protein (GFAP+) expressed gastrin de novo through a mechanism that required PKA. Gastrin-induced nuclear export of menin via cholecystokinin B receptor (CCKBR)-mediated activation of PKA. Once exported from the nucleus, menin was ubiquitinated and degraded by the proteasome. GFAP and other markers of enteric glial cells (eg, p75 and S100B), colocalized with gastrin in human duodenal gastrinomas. CONCLUSIONS: MEN1-associated gastrinomas, which develop in the submucosa, might arise from enteric glial cells through hormone-dependent PKA signaling. This pathway disrupts nuclear menin function, leading to hypergastrinemia and associated sequelae.
Authors: J S Crabtree; P C Scacheri; J M Ward; L Garrett-Beal; M R Emmert-Buck; K A Edgemon; D Lorang; S K Libutti; S C Chandrasekharappa; S J Marx; A M Spiegel; F S Collins Journal: Proc Natl Acad Sci U S A Date: 2001-01-30 Impact factor: 11.205
Authors: L V Debelenko; Z Zhuang; M R Emmert-Buck; S C Chandrasekharappa; P Manickam; S C Guru; S J Marx; M C Skarulis; A M Spiegel; F S Collins; R T Jensen; L A Liotta; I A Lubensky Journal: Cancer Res Date: 1997-06-01 Impact factor: 12.701
Authors: Martin Anlauf; Aurel Perren; Cora Lu Meyer; Sonja Schmid; Parvin Saremaslani; Marie L Kruse; Eberhard Weihe; Paul Komminoth; Philipp U Heitz; Günter Klöppel Journal: Gastroenterology Date: 2005-05 Impact factor: 22.682
Authors: Natalia A Veniaminova; Michael M Hayes; Jessica M Varney; Juanita L Merchant Journal: Am J Physiol Gastrointest Liver Physiol Date: 2012-07-05 Impact factor: 4.052
Authors: Nick Barker; Johan H van Es; Jeroen Kuipers; Pekka Kujala; Maaike van den Born; Miranda Cozijnsen; Andrea Haegebarth; Jeroen Korving; Harry Begthel; Peter J Peters; Hans Clevers Journal: Nature Date: 2007-10-14 Impact factor: 49.962
Authors: Robert Yuan; Nupur Bhattacharya; Justin A Kenkel; Jeanne Shen; Michael A DiMaio; Sreya Bagchi; Tyler R Prestwood; Aida Habtezion; Edgar G Engleman Journal: Front Oncol Date: 2020-11-13 Impact factor: 6.244
Authors: Karen Rico; Suzann Duan; Ritu L Pandey; Yuliang Chen; Jayati T Chakrabarti; Julie Starr; Yana Zavros; Tobias Else; Bryson W Katona; David C Metz; Juanita L Merchant Journal: BMJ Open Gastroenterol Date: 2021-11
Authors: Simone L Schonkeren; Tara T Küthe; Musa Idris; Ana C Bon-Frauches; Werend Boesmans; Veerle Melotte Journal: Neurogastroenterol Motil Date: 2021-07-08 Impact factor: 3.960